CN101707877B - 诊断与治疗氧化过激类病症的材料和方法 - Google Patents

诊断与治疗氧化过激类病症的材料和方法 Download PDF

Info

Publication number
CN101707877B
CN101707877B CN2008800201249A CN200880020124A CN101707877B CN 101707877 B CN101707877 B CN 101707877B CN 2008800201249 A CN2008800201249 A CN 2008800201249A CN 200880020124 A CN200880020124 A CN 200880020124A CN 101707877 B CN101707877 B CN 101707877B
Authority
CN
China
Prior art keywords
composition
application
hydrogen peroxide
acid
ulcerative colitis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2008800201249A
Other languages
English (en)
Chinese (zh)
Other versions
CN101707877A (zh
Inventor
杰伊·普拉夫达
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CN101707877A publication Critical patent/CN101707877A/zh
Application granted granted Critical
Publication of CN101707877B publication Critical patent/CN101707877B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/606—Salicylic acid; Derivatives thereof having amino groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
  • Dental Preparations (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
CN2008800201249A 2007-06-13 2008-06-13 诊断与治疗氧化过激类病症的材料和方法 Expired - Fee Related CN101707877B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US93450507P 2007-06-13 2007-06-13
US60/934,505 2007-06-13
US6374508P 2008-02-06 2008-02-06
US61/063,745 2008-02-06
PCT/US2008/007401 WO2008156671A2 (en) 2007-06-13 2008-06-13 Materials and methods for treatment and diagnosis of disorders associated with oxidative stress

Publications (2)

Publication Number Publication Date
CN101707877A CN101707877A (zh) 2010-05-12
CN101707877B true CN101707877B (zh) 2013-01-09

Family

ID=40156844

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2008800201249A Expired - Fee Related CN101707877B (zh) 2007-06-13 2008-06-13 诊断与治疗氧化过激类病症的材料和方法

Country Status (14)

Country Link
US (2) US8476233B2 (https=)
EP (2) EP2162125B1 (https=)
JP (1) JP2010529197A (https=)
KR (1) KR20100038098A (https=)
CN (1) CN101707877B (https=)
AT (1) ATE529105T1 (https=)
AU (1) AU2008266996A1 (https=)
BR (1) BRPI0812729A2 (https=)
CA (1) CA2691132C (https=)
IL (1) IL202685A0 (https=)
MX (1) MX2009013683A (https=)
NZ (1) NZ581710A (https=)
WO (1) WO2008156671A2 (https=)
ZA (1) ZA200908828B (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8916546B2 (en) 2003-08-29 2014-12-23 Therapeutic Research Llc Materials and methods for treatment and diagnosis of disorders associated with oxidative stress
US20100112088A1 (en) * 2003-08-29 2010-05-06 Jay Pravda Materials and methods for treatment of disorders associated with oxidative stress
US20130209559A1 (en) * 2012-02-13 2013-08-15 Santarus, Inc. Method for treating intestinal diseases presenting at least one inflammatory component
AU2013229990B2 (en) * 2012-03-07 2017-07-06 Santarus, Inc. Controlled-release solid dosage forms of mesalamine
CA2915793A1 (en) * 2012-07-03 2014-01-09 Jay Pravda Methods for treating, diagnosing and/or monitoring progression of oxo associated states
WO2014074995A1 (en) * 2012-11-09 2014-05-15 Scidose, Llc Enema composition for treatment of ulcerative colitis having long term stability
CN103622974B (zh) * 2013-12-05 2016-04-20 武汉武药科技有限公司 一种含美沙拉嗪和n-乙酰半胱氨酸的复方栓剂及其制备方法
AU2015379295A1 (en) 2015-01-26 2017-08-10 Dr. Falk Pharma Gmbh Enema for rectal application
ES2688119T3 (es) * 2015-07-08 2018-10-31 Dr. Falk Pharma Gmbh Formulación farmacéutica para el tratamiento de cambios inflamatorios del recto
ES2808928T3 (es) * 2015-11-27 2021-03-02 Birrbeheer B V Sales de butirato para uso en enfermedades inflamatorias
WO2018053605A1 (en) * 2016-09-26 2018-03-29 Precision Medicine Holdings Pty Ltd Diagnosis, prognosis and treatment for schizophrenia and schizoaffective psychosis
WO2018122086A1 (en) * 2016-12-28 2018-07-05 Dr. Falk Pharma Gmbh Enema for rectal application
CN108034631A (zh) * 2017-12-04 2018-05-15 武汉轻工大学 一种双氧水诱导猪小肠上皮细胞凋亡模型的建立方法
JP2019113375A (ja) * 2017-12-22 2019-07-11 サッポロホールディングス株式会社 腸内環境評価方法、大腸炎罹患リスク評価方法、及び腸内環境改善物質のスクリーニング方法
EP3741368B1 (en) * 2018-01-18 2024-03-06 Keio University Capsule for use in treating ulcerative colitis
GB201906917D0 (en) * 2019-05-16 2019-07-03 Intract Pharma Ltd Novel compositions
EP4561551A1 (en) * 2022-07-27 2025-06-04 Redox Bioscience LLC Methods and compounds for treating ulcerative colitis, systemic lupus erythematosus, sepsis, and post-sepsis syndrome
JP2025066445A (ja) * 2023-10-11 2025-04-23 国立大学法人東北大学 炎症性疾患の治療薬、及び治療薬のスクリーニング方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5082651A (en) * 1989-04-26 1992-01-21 Smith Kline & French Laboratories Limited Pharmaceutical compositions
WO2002089796A2 (en) * 2001-05-09 2002-11-14 Novartis Ag Methods for selective immunomodulation using pimecrolimus

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4211777A (en) * 1977-11-25 1980-07-08 Fisons Limited Compositions comprising a compound having sodium cromoglycate activity and aminosalicylic acid
JPS57500432A (https=) * 1980-03-20 1982-03-11
US4657900A (en) * 1983-09-27 1987-04-14 Rowell Laboratories Pharmaceutical article of manufacture comprising a bisulfite stabilized aqueous solution of 5-aminosalicylic acid and method
EP0382066A3 (de) * 1989-02-09 1992-01-08 ASTA Medica Aktiengesellschaft Verwendung von Dihydroliponsäure als Analgetikum, Antiphlogistikum und/oder Zytoprotektivum
US5378470A (en) * 1989-07-25 1995-01-03 Henning Berlin Gmbh Rectally administered pharmaceutical preparation
DE59010810D1 (de) * 1989-11-09 1998-04-16 Asta Medica Ag Arzneimittel enthaltend als Wirkstoff R-alpha-Liponsäure oder S-alpha-Liponsäure
DE4218572A1 (de) 1992-06-05 1993-12-09 Asta Medica Ag Synergistische Kombination von Arzneimitteln enthaltend als Wirkstoff alpha-Liponsäure, Dihydroliponsäure, deren Metaboliten sowie die oxidierten und reduzierten Enantiomere der alpha-Liponsäure wie die R-alpha-Liponsäure oder S-alpha-Liponsäure sowie Metaboliten der alpha-Liponsäure mit den Vitaminen A, B1-6, B12, C und E
US5569670A (en) * 1992-06-05 1996-10-29 Asta Medica Aktiengesellschaft Combination medications containing alpha-lipoic acid and related
US8178516B2 (en) * 1992-06-30 2012-05-15 Sylvan Labs, LLC Compositions and method for treatment of chronic inflammatory diseases
US20050090553A1 (en) * 1992-06-30 2005-04-28 Shapiro Howard K. Compositions and method for treatment of chronic inflammatory diseases
US6444221B1 (en) * 1992-06-30 2002-09-03 Howard K. Shapiro Methods of treating chronic inflammatory diseases using carbonyl trapping agents
JP2917799B2 (ja) 1994-03-11 1999-07-12 田辺製薬株式会社 消化管内適所放出型製剤
US5563131A (en) * 1994-08-04 1996-10-08 Pherin Corporation Pregnane steroids as neurochemical initiators of change in human hypothalamic function and related pharmaceutical compositions and methods
DE19509806A1 (de) * 1995-03-21 1996-09-26 Basf Ag Lagerstabile Arzneiformen
US5817630A (en) * 1997-03-18 1998-10-06 Austin Nutriceutical Corporation Glutathione antioxidant eye drops
US6197749B1 (en) * 1997-10-29 2001-03-06 Ajinomoto Co., Inc. Method of suppressing immune responses by reducing intracellular content of glutathione in macrophages and monocytes
US6262019B1 (en) * 1998-04-30 2001-07-17 Vit-Immune, L. C. Method of treatment of glutathione deficient mammals
CA2274943A1 (en) * 1998-06-17 1999-12-17 Stephen L. Wolman Compositions for the treatment and prevention of inflammatory diseases of the gastrointestinal tract and methods and uses thereof
AR042572A1 (es) 1999-04-02 2005-06-29 Sod Conseils Rech Applic Derivados de acido lipoico, procedimiento para su preparacion, medicamentos y composiciones farmaceuticas que los contienen y utilizacion de dichos derivados para la preparacion de los referidos medicamentos
US6664287B2 (en) * 2000-03-15 2003-12-16 Bethesda Pharmaceuticals, Inc. Antioxidants
EP1172110A3 (de) * 2000-07-07 2003-09-17 Basf Aktiengesellschaft Verwendung von Liponsäure zur Verbesserung der Bioverfügbarkeit von Mineralsalzen
US20030235571A1 (en) * 2002-06-19 2003-12-25 Gabriel Gojon-Romanillos Systemic treatment of pathological conditions resulting from oxidative stress and/or redox imbalance
CA2498581C (en) * 2002-09-10 2019-03-19 National Jewish Medical And Research Center Thioredoxin composition and uses thereof for liquefaction of mucus or sputum
US7157444B2 (en) * 2002-12-21 2007-01-02 Deanna Jean Nelson Aminosalicylate derivatives for treatment of inflammatory bowel disease
DE10305661A1 (de) 2003-02-12 2004-08-26 Degussa Ag Darreichungsform zur Kolon-spezifischen Wirkstofffreisetzung
EP1603556A2 (en) * 2003-03-06 2005-12-14 Yissum Research Development Company Of The Hebrew University Of Jerusalem Sod mimic multifunctional compounds for treating inflammatory bowel disease
US20100112088A1 (en) * 2003-08-29 2010-05-06 Jay Pravda Materials and methods for treatment of disorders associated with oxidative stress

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5082651A (en) * 1989-04-26 1992-01-21 Smith Kline & French Laboratories Limited Pharmaceutical compositions
WO2002089796A2 (en) * 2001-05-09 2002-11-14 Novartis Ag Methods for selective immunomodulation using pimecrolimus

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
MULDER CJ et al.."Beclomethasone dipropionate (3mg) versus 5-aminosalicylic acid (2g) versus the combination of both (3mg/2g) as retention enemas in active ulcerative proctitis".《European Journal of Gastroenterology & Hepatology》.1996,第8卷(第6期),第549-553页. *
SENAGORE AJ et al.."Short-Chain Fatty Acid Enemas: A Cost-Effective Alternative in the Treatment of Nonspecific Proctosigmoiditis".《Diseases of the Colon Rectum》.1992,第35卷(第10期),第923-927页. *
赵康涛等."60Co-γ射线照射大鼠损伤作用中硫辛酸对谷胱甘肽的调节与再生".《第四军医大学学报》.2003,第24卷(第11期),第1007-1009页. *

Also Published As

Publication number Publication date
EP2162125B1 (en) 2011-10-19
JP2010529197A (ja) 2010-08-26
MX2009013683A (es) 2010-04-07
EP2392321A1 (en) 2011-12-07
BRPI0812729A2 (pt) 2019-02-12
US8476233B2 (en) 2013-07-02
EP2162125A2 (en) 2010-03-17
CA2691132A1 (en) 2008-12-24
ATE529105T1 (de) 2011-11-15
WO2008156671A2 (en) 2008-12-24
US20130344184A1 (en) 2013-12-26
AU2008266996A1 (en) 2008-12-24
US20100184728A1 (en) 2010-07-22
WO2008156671A3 (en) 2009-03-12
KR20100038098A (ko) 2010-04-12
EP2162125A4 (en) 2010-08-25
CA2691132C (en) 2016-01-12
CN101707877A (zh) 2010-05-12
IL202685A0 (en) 2010-06-30
NZ581710A (en) 2012-02-24
ZA200908828B (en) 2010-12-29

Similar Documents

Publication Publication Date Title
CN101707877B (zh) 诊断与治疗氧化过激类病症的材料和方法
US7312243B1 (en) Materials and methods for treatment of gastrointestinal disorders
JP2010529197A5 (https=)
US20120322773A1 (en) Materials and methods for treatment of disorders associated with oxidative stress
Sun et al. Mitochondria in sepsis-induced AKI
Yang et al. Copper homeostasis and cuproptosis in atherosclerosis: metabolism, mechanisms and potential therapeutic strategies
Pravda Radical induction theory of ulcerative colitis
Hur et al. New mechanisms of metformin action: Focusing on mitochondria and the gut
Sid et al. Role of oxidative stress in the pathogenesis of alcohol-induced liver disease
von Montfort et al. Mitochondrial GSH determines the toxic or therapeutic potential of superoxide scavenging in steatohepatitis
Zhu et al. Oxidative stress and redox signaling mechanisms of alcoholic liver disease: updated experimental and clinical evidence
Song et al. S-adenosylmethionine (SAMe) protects against acute alcohol induced hepatotoxicity in mice☆
Birrenbach et al. Inflammatory bowel disease and smoking: a review of epidemiology, pathophysiology, and therapeutic implications
Sastre et al. Mitochondrial function in liver disease
Öktem et al. Methotrexate-induced renal oxidative stress in rats: the role of a novel antioxidant caffeic acid phenethyl ester
Lambert et al. Preservation of intestinal structural integrity by zinc is independent of metallothionein in alcohol-intoxicated mice
Yamamura et al. Panipenem, a carbapenem antibiotic, enhances the glucuronidation of intravenously administered valproic acid in rats
McCarty Nutraceutical strategies for ameliorating the toxic effects of alcohol
Liu et al. Combined contributions of impaired hepatic CYP2C11 and intestinal breast cancer resistance protein activities and expression to increased oral glibenclamide exposure in rats with streptozotocin-induced diabetes mellitus
US20230255997A1 (en) Ketogenic Diet and Ketone Supplementation for Cancer Therapy
Galicia-Moreno et al. A new opportunity for N-acetylcysteine. An outline of its classic antioxidant effects and its pharmacological potential as an epigenetic modulator in liver diseases treatment
Glade et al. A Glance At... ethanol consumption, GSH suppression, and oxidative liver damage
Yeh et al. Assessing the efficacy of the natural disaccharide trehalose in ameliorating diet-induced obesity and metabolic dysfunction
Novelli et al. Reduction of oxidative stress by a new low-molecular-weight antioxidant improves metabolic alterations in a nonobese mouse diabetes model
Hickman et al. Is vitamin E beneficial in chronic liver disease?

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20130109

Termination date: 20130613